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Members and guests of The Western Thoracic Surgical Asso-ciation, I would first of all like to thank Don Doty for thatoutstanding introduction. It is much appreciated.The dictionary definition of value includes (1) desirable usefor an important quality, (2) having intrinsic worth, and (3)worth in money or goods. The measurement of value differs
depending on one’s point of view. Measured by the cardiac patient, quantity of life
and quality of life are important. Measured by the cardiac surgeon, the ability to give
value to patients is important, and professional and personal relationships are
certainly of value. When value is measured by the health care system, cost, outcome,
and availability are the yardsticks.
Viability is (1) the ability to survive, (2) the ability to take root and grow, and (3)
the quality of having real meaning or pertinence. Once again, point of view affects
the measurement of viability. From the patient’s perspective, viability translates into
active, meaningful survival and growth potential. To the surgeon, viability means
professional development and personal fulfillment. To the health care system,
viability is the cost-effective use of resources.
For our purposes, valves are defined as membranous folds or structures that
permit blood to flow in one direction only. Many questions surround cardiac valves.
What determines value in a replacement heart valve? Is valve viability significant?
Is the ideal replacement valve made by man, by nature, or by some combination of
both?
The historical perspective of cardiac valve surgery is important to the under-
standing of current practices and future possibilities. Valve stenosis was the lesion
that was addressed initially. In 1914, Tuffier performed the first valve operation
when he dilated a stenotic aortic valve with his finger.1 The patient survived the
procedure but the long-term success of the operation is unknown.
As cardiac surgery progressed into the 1920s, Drs Cutler2 and Souttar3 both
performed closed dilation of the mitral valve to relieve mitral stenosis. In the 1940s,
Lord Brock4 developed his famous closed procedure for dilating the pulmonary
valve, and Henry Swan5 used topical hypothermia and inflow occlusion to perform
both pulmonary and aortic valvotomies. Drs Bailey6 and Harken7 achieved the first
successful, classic, closed mitral commissurotomies using primarily finger fracture
and dilation of the mitral orifice.
The need to deal with insufficiency of aortic and mitral valves led to the quest for
the ideal replacement heart valve. Charles Hufnagel8 in 1950 devised a ball valve
that was placed in the descending thoracic aorta of dogs and was found to provide
some functional relief of severe aortic regurgitation. That same year, Charles Lam9
demonstrated that a homograft valve could be placed in the descending thoracic
aorta and that the valve leaflets would function only if native aortic valve regurgi-
tation was present. In 1956, Gordon Murray10 successfully implanted an aortic
homograft in a human descending thoracic aorta as treatment for aortic valve
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insufficiency. In the early 1950s, Walton Lillehei, Charles
Gibbon, and John Kirklin all contributed much to the de-
velopment of cardiopulmonary bypass,11-13 the prerequisite
to open cardiac surgery, which was clearly a landmark in
our specialty.
Mechanical valves were introduced for human use by
Albert Starr with the collaboration of Lowell Edwards and
resulted in the first prosthetic ball-in-cage valve,14 opening
the door for other surgeons including Michael DeBakey,
Denton Cooley, and Viking Bjo¨rk to develop their own
mechanical valve prototypes.15-17 A variety of mechanical
valve types have been used over the years, including ball-
in-cage valves, tilting disc valves, and valves that look more
or less like toilet seats. However, the Bjo¨rk-Shiley valve
became the most common prosthetic valve choice for a
number of years.18,19 In 1977, St Jude Medical (St Paul,
Minn) introduced the bileaflet valve, and that has remained
the gold standard for valve replacement therapy to the
present time.20
Mechanical valves, however, do not always provide a
permanent solution. Many valves fail. The failure mode can
be different depending on valve type. Ball variance can
cause failure21 and clots on the struts of the ball-in-cage
valve can lead to thromboembolic complications,22 the
Achilles heel of mechanical valves. The tilting disc valve
can stick because of panus ingrowth and/or thrombosis.23
The actuarial late results for mechanical valves show that
the overall complication-free survival is about 50% at 18
years after implant.24 However, most of the complications
involve neither patient mortality nor the necessity to replace
the valve. With mechanical valves, structural durability is
no longer a significant problem. Unfortunately, even after
30 years of refinements, anticoagulation of mechanical
valves still is necessary. Thromboembolic complications
continue to be problematic and hemorrhagic complications
occur with anticoagulation.25 In addition, prosthetic valve
endocarditis, although uncommon, presents a very difficult
clinical problem.26
In 1969, Alain Carpentier and colleagues27 developed the
prototype porcine xenograft. Simultaneously but indepen-
dently, Warren Hancock’s group developed a slightly dif-
ferent porcine bioprosthesis.28 Although these valves do not
require long-term anticoagulant therapy, they predictably
fail over time because of calcification and perforation or
rupture of the leaflets. Actuarially, the freedom from throm-
boembolism of porcine valves without anticoagulation is
similar to that of mechanical valves with anticoagulation.
Freedom from reoperation at 15 years after implant aver-
ages only about 50%.29 There is an inverse relationship
between patient age and porcine xenograft failure, with
valve failure being more rapid in younger patients.30
In 1971, Marion Ionescu developed a valve constructed
of bovine pericardium preserved in glutaraldehyde.31 Its fate
was similar to that of porcine valves. Heavy calcification
appeared on the leaflets and they became susceptible to
tears, perforation, or both. Actuarially, only 40% of the
valves remained functional 10 years postoperatively.32
At present, the technology that supports glutaraldehyde-
fixed valves has reached a plateau. Efforts to address calci-
fication have been only marginally effective. With no major
breakthrough in sight, the limits of durability have been
reached for glutaraldehyde-preserved tissue valves.33 The
tissue calcifies rapidly in young patients, but the valves can
be useful in elderly recipients or in some situations in which
anticoagulation is contraindicated.
In 1962, Donald Ross34 developed the use of aortic valve
homografts orthotopically. Shortly thereafter, Sir Brian Bar-
ratt-Boyes,35 Wilford Bigelow,36 and Mark O’Brien37 fol-
lowed Ross’s lead and began implanting aortic homografts
in the subcoronary position. Historically, many methods
were used to preserve homograft valves, one of which
included sterilization with antibiotics and storage at 4°C; if
implanted in less than 4 to 7 days, the valve was considered
a homovital graft. Other valves were treated with -propio-
lactone, freeze-dried and lyophilized, and preserved with
acid formaldehyde, glutaraldehyde, or electron beam irra-
diation. More recently, valves have been cryopreserved with
liquid nitrogen. For practical purposes, the antibiotic-steril-
ized and the cryopreserved homografts are the only valves
with significant long-term utility. Comparing actuarial free-
dom from valve-related events for the two methods of
preservation, at 18 years’ follow-up, 76% of the cryopre-
served valves versus only 36% of antibiotic-sterilized
valves remained event free. Analysis of homograft aortic
valves and patient age at operation reveals that fewer valves
survive longer than 10 years in patients less than 20 years of
age as compared with their adult counterparts.38
A review of homograft aortic root replacement reveals a
similar pattern of valve failure in children, as only 45% of
the valves remain event free at 10 years of follow-up.39
Aortic homograft failure is typified by extensive calcifica-
tion of the aortic wall and leaflets. In fact, it is difficult to
find a photograph of a failed aortic homograft because such
homografts are removed as numerous small pieces of rock-
hard, calcified tissue.
In 1967, Donald Ross40 performed the first pulmonary
autograft procedure, the operation that now bears his name.
The operation involves excision of the native pulmonary
valve for reimplantation into the left ventricular outflow
tract to replace the diseased aortic valve. The pulmonary
valve is then replaced with a homograft; initially an aortic
homograft was used, and now pulmonary homografts are
commonly used. In the United States, Ronald Elkins began
to perform this operation extensively in the early 1980s and
has become the national expert on the pulmonary autograft
procedure.41 Actuarial valve survival in the series reported
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by Elkins’ group42 shows that 96% of the valves remain
functional 10 years postoperatively.
Discussion of the pulmonary autograft procedure man-
dates that we turn our attention to right ventricle–pulmonary
artery conduits. Several types commonly have been used:
(1) the porcine valved conduit, which is a glutaraldehyde-
preserved porcine valve in a Dacron conduit; (2) the aortic
homograft; and (3) the pulmonary homograft, which be-
came popular after the development of cryopreservation.
For porcine conduits in the right ventricular outflow tract,
actuarial freedom from reoperation is 30% to 40% at 15 to
20 years, respectively. Analysis of freedom from reopera-
tion by lesion reveals that the anomalies that require conduit
implantation at younger ages display a more rapid failure
rate. Again, the mode of failure involves calcification,
pseudointima formation, and leaflet perforation or frac-
ture.43
Aortic homografts implanted in the right ventricular out-
flow tract have similar late results, with approximately 40%
actuarial valve survival at 10 years’ follow-up. Pulmonary
homografts have proven more durable, with 80% actuarial
valve survival at 10 years after implant.44 Pulmonary ho-
mograft valves therefore display good durability and hemo-
dynamic performance. However, they also stimulate an im-
mune response, and this undoubtedly affects their
durability.45 Also, homograft recipients might become sen-
sitized to the foreign tissue, which would make future
cardiac transplantation more difficult and hazardous. The
degree of immunosuppression that would be required to
prevent this immune response is undesirable and no less
hazardous than anticoagulation.
If we look for a moment at calcification of the native
bicuspid aortic valve, we see that abnormal blood flow
rheology results in wear and tear of the leaflets and predis-
poses them to calcification, primarily on the aortic side of
the valve.46 This has technical implications for the implan-
tation of tissue valves. Tissue valve implantation techniques
vary in their reliability to produce an anatomically normal
blood flow pathway. The distortion leads to turbulent blood
flow, and abnormal blood flow predisposes to an inflamma-
tory process that leads to calcification in the same fashion as
occurs with a native bicuspid aortic valve. There are three
techniques of reconstruction for the right ventricular out-
flow tract. In repair of truncus arteriosus, the proximal end
of the conduit is placed on the surface of the ventricle,
which results in a more tortuous blood flow pathway and
greater turbulence. When the conduit can be placed partially
into the native right ventricular outflow tract, as in tetralogy
of Fallot repair, distortion is less. The most anatomic and
least distorted application is found in the Ross procedure, in
which the homograft is placed precisely in its anatomic
location.47
With respect to the left ventricular outflow tract, the
subcoronary implantation technique, although clinically re-
producible by some surgeons, does not reliably create a
normal hemodynamic pathway. Slightly more reliable is the
inclusion cylinder technique. Certainly, the most reliable
method of preserving normal anatomy and therefore normal
hemodynamic flow across the valve is aortic root replace-
ment with coronary artery reimplantation.48
Consider, for a moment, immunology and its relationship
to implanted heart valves. One can reasonably assume that
immunology is not relevant to mechanical valves. Some
believe that it also is not relevant to glutaraldehyde-pre-
served tissue valves. However, a more careful exploration
of the issue shows that although glutaraldehyde fixation
kills the cells, it does not remove cellular proteins, and
although collagen cross-linking masks antigenic expression,
it also prevents repopulation by the host. Therefore, it is
possible if not likely that glutaraldehyde-preserved tissue
valves do elicit an immune response over time. Donor cell
viability in a tissue valve also is significant in that it might
stimulate an increased immune response, and viable endo-
thelium is known to be a strong antigen in the clinical
situation.49,50
In 2000, John Hawkins and his colleagues51 in Salt Lake
City conducted an interesting study in patients undergoing
pediatric cardiac surgery. They compared a group of chil-
dren who received cryopreserved homograft tissue with a
control group who underwent cardiac surgery but did not
receive homograft tissue. They measured panel reactive
antibody (PRA) levels before surgery and at 1 month, 3
months, and 12 months postoperatively. They found that the
control patients had low PRA levels at all times. The ho-
mograft recipients had low levels preoperatively but rapidly
increasing levels postoperatively; PRA levels peaked at 3
months and leveled off at 1 year at approximately 85%.
So, what is the current status of cardiac valve replace-
ment? Clearly, the quest for the ideal replacement valve
continues. A new bileaflet mechanical valve is available
from ATS Medical, Inc (Minneapolis, Minn). It is similar to
the St Jude Medical valve but has a different hinge mech-
anism that is theoretically less thrombogenic.52 Also avail-
able are a new pericardial valve53 and stentless porcine
valves.54,55 The group in Boston is developing a synthetic
scaffold to use as a matrix for cellular repopulation in
vitro,56 and a decellularized tissue matrix valve of xenograft
or homograft origin is being developed.
The natural matrix decellularization process includes a
gentle enzymatic washing during which the cellular protein
components of the graft are removed while the collagen
matrix remains intact. No fixation or cross-linking of the
collagen matrix occurs. The tissue is then sterilized with
gamma-irradiation and cryopreserved. The principles of de-
cellularization are (1) to preserve the biomechanical and
biochemical properties of the matrix, (2) to presume that an
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acellular collagen matrix is a poor antigen, (3) to assume
that a matrix that is not cross-linked or damaged by an
immune reaction is receptive to host recellularization, and
(4) to conclude that a recellularized matrix should be dura-
ble for the long term.
An acellularized xenograft construct has been devel-
oped.57,58 Because of difficulty with decellularization of
porcine myocardium, three size- and symmetry-matched
decellularized, porcine, noncoronary cusp units can be su-
tured together longitudinally. The anterior mitral leaflet
remnants are used to form the inflow conduit. These valves
were implanted into the right ventricular outflow tract of
weanling sheep. Compared with a fresh leaflet that shows
normal cellularity, a decellularized leaflet shows no nuclear
staining and therefore no cellularity. Recellularization with
sheep cells began before 150 days and progressed to a near
normal pattern at 336 days. In summary, the acellular xeno-
graft is a stentless symmetrical design, has excellent hydro-
dynamic performance, has retained biomechanical proper-
ties, and is initially durable in xenogenic recipients
including sheep and human beings. Leaflet recellularization
has been demonstrated to occur spontaneously in vivo.
Decellularization of homografts59 was explored because
homografts are more immediately available and do not have
to go through the extensive premarket approval process that
is required of composite xenografts. In vitro testing dem-
onstrates that decellularized homografts are comparable
with traditional cryopreserved homografts in conduit and
leaflet strength, handling and suturing characteristics, and
hydrodynamic performance. In animal studies, decellular-
ized homografts in the pulmonary position exhibit normal
function as demonstrated by echocardiography. They dem-
onstrate spontaneous cellular repopulation of both leaflet
and conduit tissues, and the new cells differentiate into a
mature population of host structural and contractile cells.
Procollagen staining reveals that the fibroblasts are func-
tioning and synthesizing procollagen at 3 months and con-
tinuing at 6 months after implant.
Decellularized homografts have been implanted for 2
years on a clinical trial basis. The objective of the clinical
study is to evaluate the graft’s hemodynamic function and to
assess host immune response by measuring PRA levels at 1
and 3 months postoperatively. A negative PRA level is
defined as less than 10%. A portion of this study includes 56
patients who had had no previous replacement valve and
received a decellularized homograft. Fifty-one of the pa-
tients had a negative preoperative PRA measurement, 1 had
a positive measurement, and 4 were not assessed. Postop-
eratively, 46 of the 51 negative PRA levels remained neg-
ative, 1 turned positive, and 4 were not measured. The
patient whose readings turned positive had had multiple
pregnancies and might have been sensitized by blood trans-
fusions. In summary, a decellularized homograft is a colla-
gen matrix that is not cross-linked and is devoid of cellular
proteins. HLA antigen levels are reduced, thus decreasing or
eliminating the host antibody response. Because there is no
inflammatory response, the matrix remains undisturbed, al-
lowing for host cellular repopulation, and host sensitization
is reduced or eliminated.
In the current era, the economics of cardiac valve re-
placement60 cannot be ignored. Let us first examine me-
chanical valves. If we assume an average 25-year survival
after valve replacement, the cost of anticoagulation per
patient is approximately $13,500. Clinic visits, international
normalized ratio measurements, and so forth amount to
about $25,000 over the same period. A complication rate of
approximately 4% per patient-year equates to 1 incident per
25 years at a conservative estimated cost per complication
of $7500. Thus, the total conservative estimate of cost per
patient lifetime is $46,000 after mechanical valve implan-
tation. If 30,000 mechanical aortic valves are implanted per
year, the attrition rate approximates the implantation rate,
and the yearly cost is similar during the 25-year life span,
the cost per year then amounts to 30,000 valves times
$46,000 or $1.38 billion and the cost to the health care
system over 25 years becomes $34.5 billion.
Let us also assess the economic impact of cryopreserved
homograft implantation. In the United States, approximately
40,000 homografts have been implanted. A 75% late sur-
vival equates to 30,000 valves. Assume that 80% will re-
quire one reoperation and 40% will require a second reop-
eration. Hospital payments for the reoperations average
$35,000, and physician payments average $5500. In a 25-
year life span there are 36,000 reoperations at approxi-
mately $40,000 per operation or a $1.5 billion cost to the
health care system.
Is there an ideal valve? It is possible. Tissue-engineered
valves combine technology with nature. Value to the patient
equates to enhanced viability that is achieved through nor-
mal cardiac function with growth potential and decreased
complications and reoperations. The implication for sur-
geons is a reduced case load secondary to fewer reopera-
tions, but we can tolerate that since it means that our
patients are having better outcomes. With valve implants
that require recellularization, the need to restore normal
anatomy is more important and more technically demand-
ing, but these valves might produce a lifelong solution for a
patient who requires valve replacement.
Value to the health care system includes good patient
outcome and substantial long-term dollar savings. Avail-
ability potential increases as we progress from a homograft
matrix to a xenograft matrix and ultimately to a totally
synthetic matrix. Although the ideal replacement heart
valve is not yet a reality, the theoretical potential exists for
the first time.
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